طبيب أعصاب للأطفال مع خبرة في الصرع والصداع واضطرابات النوم وطب أعصاب الأطفال ومراقبة النمو. حصل على شهادة الطب من كلية الطب في جامعة جراح باشا في إسطنبول عام 2006 ، وحصل على تدريب مساعد ثانوي في طب الأعصاب للأطفال من جامعة إسطنبول ميديبول في عام 2017. أكمل تدريب الطبيب المتخصص من مستشفى شانلي أورفا سوروك الحكومي في عام 2012 ومستشفى اسطنبول غازي عثمان باشا للتدريب والبحوث في عام 2017. حاصل على شهادات مختلفة بما في ذلك التأهيل في اختبار دنفر التنموي 2 ، وشهادة الممارس في برنامج الإنعاش العصبي ، ودورات مختلفة في طب أعصاب الأطفال ، والصرع ، وعلم المناعة العصبية ، ومخطط كهربية العضل ، وعلم الوراثة الأساسية. عضو الجمعية التركية لطب أعصاب الأطفال.
اقرأ المزيدطبيب أعصاب للأطفال مع خبرة في الصرع والصداع واضطرابات النوم وطب أعصاب الأطفال ومراقبة النمو. حصل على شهادة الطب من كلية الطب في جامعة جراح باشا في إسطنبول عام 2006 ، وحصل على تدريب مساعد ثانوي في طب الأعصاب للأطفال من جامعة إسطنبول ميديبول في عام 2017. أكمل تدريب الطبيب المتخصص من مستشفى شانلي أورفا سوروك الحكومي في عام 2012 ومستشفى اسطنبول غازي عثمان باشا للتدريب والبحوث في عام 2017. حاصل على شهادات مختلفة بما في ذلك التأهيل في اختبار دنفر التنموي 2 ، وشهادة الممارس في برنامج الإنعاش العصبي ، ودورات مختلفة في طب أعصاب الأطفال ، والصرع ، وعلم المناعة العصبية ، ومخطط كهربية العضل ، وعلم الوراثة الأساسية. عضو الجمعية التركية لطب أعصاب الأطفال.
With more than 120 medical publications on stem cells in preeminent medical journals, Professor Yvan Torrente is considered one of the world’s best scientists in regenerative medicine, genetic engineering of stem cells and advanced gene therapies for degenerative diseases. Prof. Torrente is currently the director of the Neurology department of the “Policlinico” Hospital in Milan as well as the head of the cell laboratory for the advanced therapy medical products in Milan.
In addition, Yvan is a professor in neurology at the University of Milan. Prof. Torrente is assisted by a team of highly trained and well-regarded doctors, biologists and researchers in the laboratory in Milan who provide external assistance and consultancy to our medical team. Specifically, over the years, Professor Torrente has helped our team to develop GMP compliant and high-quality safety standards in complex research projects, applying the same to medicinal and clinical products catered for specific uses.
Professor Torrente is currently leading and supervising several clinical trials in Europe on stem cell use in human beings as well as other advanced therapy medical products. He also provides assistance and consultancy services to several other hospitals worldwide, especially in the U.S., Canada and the U.K. Finally, Yvan is a well-known speaker at prestigious events, seminars and symposiums worldwide.
With more than 120 medical publications on stem cells in preeminent medical journals, Professor Yvan Torrente is considered one of the world’s best scientists in regenerative medicine, genetic engineering of stem cells and advanced gene therapies for degenerative diseases. Prof. Torrente is currently the director of the Neurology department of the “Policlinico” Hospital in Milan as well as the head of the cell laboratory for the advanced therapy medical products in Milan.
In addition, Yvan is a professor in neurology at the University of Milan. Prof. Torrente is assisted by a team of highly trained and well-regarded doctors, biologists and researchers in the laboratory in Milan who provide external assistance and consultancy to our medical team. Specifically, over the years, Professor Torrente has helped our team to develop GMP compliant and high-quality safety standards in complex research projects, applying the same to medicinal and clinical products catered for specific uses.
Professor Torrente is currently leading and supervising several clinical trials in Europe on stem cell use in human beings as well as other advanced therapy medical products. He also provides assistance and consultancy services to several other hospitals worldwide, especially in the U.S., Canada and the U.K. Finally, Yvan is a well-known speaker at prestigious events, seminars and symposiums worldwide.
Dr. Mehdi Afrit is a Medical Oncologist who practices at Burjeel Specialty Hospital in Sharjah. He has over 11 years of experience caring for and managing cancer patients. He has extensive experience providing chemotherapy, hormonal therapy, immunotherapy, and targeted therapy to patients. He earned a Certificate of Medical Oncology from the Gustave Roussy Institute in Paris, France, where he received training in antitumor chemotherapy and cancer medical treatment. Additionally, he holds an international certificate in breast diseases. He also has a certificate in Good Clinical Practice from Trans Celerate Biopharma Inc. and a certificate in Clinical Trial Management: Good Clinical Practice from the Faculty of Pharmaceutical Medicine of the Royal College of Physicians. He previously worked for over five years as an Assistant Professor of Medical Oncology at Tunis’s Faculty of Medicine. He later practiced as a Consultant, Medical Oncologist for six years at Arianna’s hospital in Tunisia. He later worked for two years as a Specialist Medical Oncologist at Zulekha Hospital. He was also an investigator in three international clinical trials and holds clinical trial auditing and CRO certifications and a GCP Training Certificate from 2016. He is a member in good standing of the Emirates Oncology Society (EOS), the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). His clinical expertise includes but is not limited to the following:
Dr. Mehdi Afrit is a Medical Oncologist who practices at Burjeel Specialty Hospital in Sharjah. He has over 11 years of experience caring for and managing cancer patients. He has extensive experience providing chemotherapy, hormonal therapy, immunotherapy, and targeted therapy to patients. He earned a Certificate of Medical Oncology from the Gustave Roussy Institute in Paris, France, where he received training in antitumor chemotherapy and cancer medical treatment. Additionally, he holds an international certificate in breast diseases. He also has a certificate in Good Clinical Practice from Trans Celerate Biopharma Inc. and a certificate in Clinical Trial Management: Good Clinical Practice from the Faculty of Pharmaceutical Medicine of the Royal College of Physicians. He previously worked for over five years as an Assistant Professor of Medical Oncology at Tunis’s Faculty of Medicine. He later practiced as a Consultant, Medical Oncologist for six years at Arianna’s hospital in Tunisia. He later worked for two years as a Specialist Medical Oncologist at Zulekha Hospital. He was also an investigator in three international clinical trials and holds clinical trial auditing and CRO certifications and a GCP Training Certificate from 2016. He is a member in good standing of the Emirates Oncology Society (EOS), the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). His clinical expertise includes but is not limited to the following:
Dr. Corrado Lodigiani has been assistant at the Thrombosis Centre of Humanitas research Hospital from 1998 to 2013 and he became Unit Director in 2013.
Humanitas Thrombosis Center is a state-of-the-art service for the proper management of the diagnosis and therapy of venous thromboembolic pathology (deep and superficial venous thrombosis, pulmonary thromboembolism, visceral venous thrombosis) and arterial (myocardial infarction, cerebral stroke, peripheral arterial disease).
Other also rare diseases treated are atypical thrombosis, such as the vascular circulation of the retina, the hearing system and the placental circulation during pregnancy.
Dr. Lodigiani adopts the multidisciplinary approach and works in collaboration with all medical and surgical specialties. In particular, he carries out clinical and instrumental diagnostics (vascular ecocolordoppler) and research on the causes, diagnosis and therapy of thrombotic and bleeding disorders, congenital and acquired. His clinical activity also involves the diagnosis and management of patients suffering from bleeding diseases, such as haemophilia, von Willebrand’s disease and platelet diseases.
In recent years, he has devoted himself with particular interest to the testing, in the role of Principal Investigator in International Clinical Studies, of new antithrombotic drugs and, above all, anticoagulants, which are about to be marketed and will constitute a valid and safe alternative to traditional oral anticoagulant therapy (DOACs). He is also working, with great interest, on researching the causes of idiopathic infertility and the usefulness and effectiveness of some therapeutic strategies, such as the use of anticoagulant drugs, improving the results of artificial insemination procedures. He is the author of numerous articles in international scientific journals and speaker at numerous national and international conferences.
اقرأ المزيدDr. Corrado Lodigiani has been assistant at the Thrombosis Centre of Humanitas research Hospital from 1998 to 2013 and he became Unit Director in 2013.
Humanitas Thrombosis Center is a state-of-the-art service for the proper management of the diagnosis and therapy of venous thromboembolic pathology (deep and superficial venous thrombosis, pulmonary thromboembolism, visceral venous thrombosis) and arterial (myocardial infarction, cerebral stroke, peripheral arterial disease).
Other also rare diseases treated are atypical thrombosis, such as the vascular circulation of the retina, the hearing system and the placental circulation during pregnancy.
Dr. Lodigiani adopts the multidisciplinary approach and works in collaboration with all medical and surgical specialties. In particular, he carries out clinical and instrumental diagnostics (vascular ecocolordoppler) and research on the causes, diagnosis and therapy of thrombotic and bleeding disorders, congenital and acquired. His clinical activity also involves the diagnosis and management of patients suffering from bleeding diseases, such as haemophilia, von Willebrand’s disease and platelet diseases.
In recent years, he has devoted himself with particular interest to the testing, in the role of Principal Investigator in International Clinical Studies, of new antithrombotic drugs and, above all, anticoagulants, which are about to be marketed and will constitute a valid and safe alternative to traditional oral anticoagulant therapy (DOACs). He is also working, with great interest, on researching the causes of idiopathic infertility and the usefulness and effectiveness of some therapeutic strategies, such as the use of anticoagulant drugs, improving the results of artificial insemination procedures. He is the author of numerous articles in international scientific journals and speaker at numerous national and international conferences.